
Claims


1. A composition comprising Compound A ((R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile) of Formula (A):



(A)

or a pharmaceutically acceptable salt thereof; and

Compound B (*N*-hydroxy-3-[4-[[[2-(2-methyl-1*H*-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide) of Formula (B):



(B),

or a pharmaceutically acceptable salt thereof.

2. The composition of claim 1, further comprising pharmaceutically acceptable carrier(s).

3. The composition of claim 1 in a single formulation or unit dosage form.

4. A method of treating cancer in a subject in need thereof comprising administering to the subject an effective amount of the composition of any one of the above claims.

5. The method of claim 4, wherein the cancer is a myeloproliferative neoplasm.

6. The method of claim 5, wherein the myeloproliferative neoplasm is selected from the group consisting of chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary or idiopathic myelofibrosis (PMF), chronic neutrophilic leukemia, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, hypereosinophilic syndrome, systemic mastocytosis, and atypical chronic myelogenous leukemia.

7. The method of any of claims 4-6, wherein the subject is human.

8. The method of any of claims 4-6, wherein the treatment comprises co-administering Compound A and Compound B.

9. The method of any of claims 4-6, wherein Compound A and Compound B are in a single formulation or unit dosage form.

10. The method of any of claims 4-6, wherein the treatment comprises administering Compound A and Compound B at substantially the same time.

11. The method of any of claims 4-6, wherein the treatment comprises administering Compound A and Compound B at different times.

12. The method of claim 11, wherein Compound B is administered to the subject, followed by administration of Compound A.

13. The method of claim 11, wherein Compound A is administered to the subject, followed by administration of Compound B.

14. The method of any of claims 8-10, wherein Compound A and Compound B are in separate formulations or unit dosage forms.

15. The method of claim 7, wherein Ruxolitinib is given 3-7 mg BID, Panobinostat is administered 8-12 mg TIW QOW.

16. The method of claim 7, wherein Ruxolitinib is given 8-12 mg BID, Panobinostat is administered 8-12 mg TIW QOW.

17. The method of claim 7, wherein Ruxolitinib is given 10-20 mg BID, Panobinostat is administered 8-12 mg TIW QOW.

18. The method of claim 7, wherein Ruxolitinib is given 10-20 mg BID, Panobinostat is administered 10-20 mg TIW QOW.


19. The method of claim 7, wherein Ruxolitinib is given 10-20 mg BID, Panobinostat is administered 10-30 mg TIW QOW.

20. The method of claim 7, wherein Ruxolitinib is given 10-20 mg BID, Panobinostat is administered 10-30 mg TIW QOW.

21. The method of claim 7, wherein Ruxolitinib is given 10-20 mg BID, Panobinostat is administered 20-40 mg TIW QOW.


Claims

1. A composition comprising Compound A ((R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl-propanenitrile) of Formula (A):



(A)

or a pharmaceutically acceptable salt thereof; and
Compound B (*N*-hydroxy-3-[4-[[[2-(2-methyl-1*H*-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide) of Formula (B):



(B),

or a pharmaceutically acceptable salt thereof, for use in the treatment of a cancer, wherein the cancer is myeloproliferative neoplasm or multiple myeloma.

2. The composition for use according to claim 1, further comprising pharmaceutically acceptable carrier(s).

3. The composition for use according to claim 1 wherein the composition is in a single formulation or unit dosage form.

4. The composition for use in the treatment of cancer according to claim 1, wherein the cancer is multiple myeloma.

5. The composition for use in the treatment of cancer according to claim 1, wherein the cancer is a myeloproliferative neoplasm.

6. The composition for use in the treatment of cancer according to claim 5, wherein the myeloproliferative neoplasm is selected from the group consisting of chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary or idiopathic myelofibrosis (PMF), chronic neutrophilic leukemia, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, hypereosinophilic syndrome, systemic mastocytosis, and atypical chronic myelogenous leukemia.

7. The composition for use in the treatment of cancer according to any of claims 4-6, wherein the composition is to be administered to a human.

8. The composition for use in the treatment of cancer according to any of claims 4-6, wherein Compound A and Compound B are to be co-administered.

9. The composition for use in the treatment of cancer according to any of claims 4-6, wherein Compound A and Compound B are in a single formulation or unit dosage form.

10. The composition for use in the treatment of cancer according to any of claims 4-6, wherein the Compound A and Compound B are to be administed at substantially the same time.

11. The composition for use in the treatment of cancer according to any of claims 4-6, wherein the Compound A and Compound B are to be administered at different times.

12. The composition for use in the treatment of cancer according to any of claims 8-10, wherein Compound A and Compound B are in separate formulations or unit dosage forms.